Which has stronger valuation & earnings, ENGN or RZLT?

Rezolute is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$1.13 N/A Rezolute N/A N/A -$77.59M -$0.76 N/A

Is ENGN or RZLT more profitable?

enGene's return on equity of -27.97% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -27.97% -22.65% Rezolute N/A -62.99% -57.94%

Does the media prefer ENGN or RZLT?

In the previous week, enGene had 3 more articles in the media than Rezolute. MarketBeat recorded 19 mentions for enGene and 16 mentions for Rezolute. Rezolute's average media sentiment score of 0.38 beat enGene's score of 0.01 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 2 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ENTX or ENGN?

Entera Bio has higher revenue and earnings than enGene. Entera Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio $40K 11,565.68 -$11.44M -$0.35 N/A enGene N/A N/A -$117.30M -$1.13 N/A

Is ENTX or ENGN more profitable?

enGene's return on equity of -27.97% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% enGene N/A -27.97% -22.65%

Does the media favor ENTX or ENGN?

In the previous week, enGene had 15 more articles in the media than Entera Bio. MarketBeat recorded 19 mentions for enGene and 4 mentions for Entera Bio. enGene's average media sentiment score of 0.01 beat Entera Bio's score of 0.00 indicating that enGene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, KMDA or ENGN?

Kamada has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $191.85M 2.42 $20.20M $0.38 21.26 enGene N/A N/A -$117.30M -$1.13 N/A

Is KMDA or ENGN more profitable?

Kamada has a net margin of 11.60% compared to enGene's net margin of 0.00%. Kamada's return on equity of 8.37% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% enGene N/A -27.97% -22.65%

Does the media favor KMDA or ENGN?

In the previous week, enGene had 14 more articles in the media than Kamada. MarketBeat recorded 19 mentions for enGene and 5 mentions for Kamada. Kamada's average media sentiment score of 0.04 beat enGene's score of 0.01 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, TECX or ENGN?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A enGene N/A N/A -$117.30M -$1.13 N/A

Is TECX or ENGN more profitable?

enGene's return on equity of -27.97% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -35.26% -33.59% enGene N/A -27.97% -22.65%

Does the media refer more to TECX or ENGN?

In the previous week, enGene had 16 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 19 mentions for enGene and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.53 beat enGene's score of 0.01 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ENGN or EDIT more profitable?

enGene has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. enGene's return on equity of -27.97% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -27.97% -22.65% Editas Medicine -157.32% -196.63% -38.17%

Does the media prefer ENGN or EDIT?

In the previous week, enGene had 4 more articles in the media than Editas Medicine. MarketBeat recorded 19 mentions for enGene and 15 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.55 beat enGene's score of 0.01 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

enGene (ENGN) Competitors

$1.73 -0.05 (-2.81%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.77 +0.04 (+2.20%)

As of 10/9/2026 04:20 PM Eastern

Compare

ENGN vs. RZLT, ENTX, KMDA, TECX, and EDIT

Should you buy enGene stock or one of its competitors? enGene's main competitors and comparable companies include Rezolute (RZLT), Entera Bio (ENTX), Kamada (KMDA), Tectonic Therapeutic (TECX), and Editas Medicine (EDIT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does enGene compare to Rezolute?

enGene (NASDAQ:ENGN) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

In the previous week, enGene had 3 more articles in the media than Rezolute. MarketBeat recorded 19 mentions for enGene and 16 mentions for Rezolute. Rezolute's average media sentiment score of 0.38 beat enGene's score of 0.01 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	2 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.2% of enGene shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rezolute is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$1.13	N/A
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A

enGene presently has a consensus target price of $11.05, suggesting a potential upside of 538.47%. Rezolute has a consensus target price of $11.22, suggesting a potential upside of 130.44%. Given enGene's higher probable upside, equities research analysts plainly believe enGene is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Rezolute	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

enGene's return on equity of -27.97% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-27.97%	-22.65%
Rezolute	N/A	-62.99%	-57.94%

enGene has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Summary

Rezolute beats enGene on 8 of the 13 factors compared between the two stocks.

How does enGene compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

In the previous week, enGene had 15 more articles in the media than Entera Bio. MarketBeat recorded 19 mentions for enGene and 4 mentions for Entera Bio. enGene's average media sentiment score of 0.01 beat Entera Bio's score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 10.6% of Entera Bio shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Entera Bio has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, enGene has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market.

enGene's return on equity of -27.97% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
enGene	N/A	-27.97%	-22.65%

Entera Bio has higher revenue and earnings than enGene. Entera Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	11,565.68	-$11.44M	-$0.35	N/A
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

Entera Bio currently has a consensus price target of $9.60, indicating a potential upside of 260.90%. enGene has a consensus price target of $11.05, indicating a potential upside of 538.47%. Given enGene's higher possible upside, analysts clearly believe enGene is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Entera Bio and enGene tied by winning 7 of the 14 factors compared between the two stocks.

How does enGene compare to Kamada?

Kamada (NASDAQ:KMDA) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Kamada has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$191.85M	2.42	$20.20M	$0.38	21.26
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

Kamada has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, enGene has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

Kamada has a net margin of 11.60% compared to enGene's net margin of 0.00%. Kamada's return on equity of 8.37% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
enGene	N/A	-27.97%	-22.65%

Kamada currently has a consensus target price of $13.50, suggesting a potential upside of 67.08%. enGene has a consensus target price of $11.05, suggesting a potential upside of 538.47%. Given enGene's higher probable upside, analysts plainly believe enGene is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, enGene had 14 more articles in the media than Kamada. MarketBeat recorded 19 mentions for enGene and 5 mentions for Kamada. Kamada's average media sentiment score of 0.04 beat enGene's score of 0.01 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

20.4% of Kamada shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Kamada beats enGene on 11 of the 14 factors compared between the two stocks.

How does enGene compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

enGene's return on equity of -27.97% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
enGene	N/A	-27.97%	-22.65%

Tectonic Therapeutic has a beta of 3.28, meaning that its stock price is 228% more volatile than the broader market. Comparatively, enGene has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market.

In the previous week, enGene had 16 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 19 mentions for enGene and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.53 beat enGene's score of 0.01 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tectonic Therapeutic currently has a consensus price target of $77.80, indicating a potential upside of 233.48%. enGene has a consensus price target of $11.05, indicating a potential upside of 538.47%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Tectonic Therapeutic and enGene tied by winning 7 of the 14 factors compared between the two stocks.

How does enGene compare to Editas Medicine?

enGene (NASDAQ:ENGN) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

enGene has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. enGene's return on equity of -27.97% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-27.97%	-22.65%
Editas Medicine	-157.32%	-196.63%	-38.17%

64.2% of enGene shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, enGene had 4 more articles in the media than Editas Medicine. MarketBeat recorded 19 mentions for enGene and 15 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.55 beat enGene's score of 0.01 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

enGene has a beta of -0.29, meaning that its share price is 129% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

enGene currently has a consensus target price of $11.05, suggesting a potential upside of 538.47%. Editas Medicine has a consensus target price of $5.83, suggesting a potential upside of 101.15%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

enGene has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$1.13	N/A
Editas Medicine	$40.52M	10.99	-$160.06M	-$0.75	N/A

Summary

enGene beats Editas Medicine on 8 of the 15 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$115.94M	$3.93B	$7.26B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-1.53	13.55	274.99	26.14
Price / Sales	N/A	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	0.67	17.17	11.22	6.33
Net Income	-$117.30M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-10.82%	-1.34%	-0.89%	-1.40%
1 Month Performance	-2.26%	-8.45%	-4.42%	-3.47%
1 Year Performance	-79.38%	14.02%	7.03%	1.18%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	3.7357 of 5 stars	$1.73 -2.8%	$11.05 +538.5%	-80.5%	$115.94M	N/A	N/A	82
RZLT Rezolute	3.4091 of 5 stars	$4.89 +5.3%	$11.22 +129.7%	-44.8%	$472.49M	N/A	N/A	58	Analyst Forecast
ENTX Entera Bio	3.1796 of 5 stars	$2.72 +8.6%	$9.60 +253.6%	+6.0%	$472.20M	N/A	N/A	21	Short Interest Increase
KMDA Kamada	4.9047 of 5 stars	$8.07 +3.7%	$13.50 +67.3%	+16.6%	$464.11M	$180.46M	21.24	462	Analyst Upgrade
TECX Tectonic Therapeutic	2.9466 of 5 stars	$23.41 +2.9%	$77.80 +232.4%	+36.6%	$457.55M	N/A	N/A	60	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors